Elsevier

Progress in Neurobiology

Volume 43, Issue 6, August 1994, Pages 537-565
Progress in Neurobiology

A vitamin as neuromodulator: Ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission

https://doi.org/10.1016/0301-0082(94)90052-3Get rights and content

First page preview

First page preview
Click to open first page preview

References (385)

  • K.G. Bensch et al.

    On a possible mechanism of action of ascorbic acid: formation of ionic bonds with biological molecules

    Biochem. biophys. Res. Commun.

    (1981)
  • S. Bernath

    Calcium-independent release of amino acid neurotransmitters—fact or artifact

    Prog. Neurobiol.

    (1992)
  • R.D. Blakely et al.

    Neuroleptics increase striatal catecholamine metabolites but not ascorbic acid in dialyzed perfusate

    Brain Res.

    (1984)
  • M.G. Boutelle et al.

    Rapid changes in striatal ascorbate in response to tail-pinch monitored by constant potential voltammetry

    Neuroscience

    (1989)
  • M.P. Brazell et al.

    Intracerebral injection of ascorbate oxidase-effect on in vivo electrochemical recordings

    Brain Res.

    (1982)
  • M.H. Briggs et al.

    Urinary oxalate and vitamin C supplements

    The Lancet

    (1973)
  • G.R. Buettner

    The pecking order of free radicals and antioxidants—lipid peroxidation, alpha-tocopherol, and ascorbate

    Arch. Biochem. Biophys.

    (1993)
  • J. Cammack et al.

    The pharmacological profile of glutamate-evoked ascorbic acid efflux measured by in vivo electrochemistry

    Brain Res.

    (1991)
  • J. Cammack et al.

    Antioxidants prevent the interaction of 3,4-dydroxyphenylacetic acid at the dopamine-D2 receptor

    Eur. J. Pharmac.

    (1991)
  • D.J. Carey et al.

    Schwann-cell myelination in a chemically defined medium-demonstration of a requirement for additives that promote schwann-cell extracellular-matrix formation

    Dev. Brain Res.

    (1987)
  • M. Carlsson et al.

    Interactions between glutamatergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson's disease

    Trends Neurosci.

    (1990)
  • M. Carlsson et al.

    Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems

    Pharmac. Biochem. Behav.

    (1990)
  • C.J. Carter

    Topographic distribution of possible glutamatergic pathways from the frontal cortex to the striatum and substantia nigra in rats

    Neuropharmacology

    (1982)
  • B. Chan et al.

    Ascorbate injury and EDTA (or manganese) protection of D-2 dopamine receptors

    Eur. J. Pharmac.

    (1982)
  • M.-F. Chesselet

    Presynaptic regulation of neurotransmitter release in the brain: facts and hypothesis

    Neuroscience

    (1984)
  • N.J. Chinoy

    Ascorbic acid levels in mammalian tissues and its metabolic significance

    Comp. Biochem. Physiol.

    (1972)
  • L.A. Chiodo et al.

    Interactions between dopamine and amino acid-induced excitation and inhibition in the striatum

    Brain Res.

    (1986)
  • D.W. Choi

    Glutamate neurotoxicity and diseases of the nervous system

    Neuron

    (1988)
  • O. Civelli et al.

    Molecular biology of the dopamine receptors

    Eur. J. Pharmac.

    (1991)
  • J.A. Clemens et al.

    Changes in brain chemistry produced by dopaminergic agents: in vivo electrochemical monitoring reveals opposite changes in anesthetized vs unanesthetized rats

    Brain Res.

    (1983)
  • J.A. Clemens et al.

    Brain dialysis in conscious rats confirms in vivo electrochemical evidence that dopaminergic stimulation releases ascorbate

    Life Sci.

    (1984)
  • G.G.S. Collins et al.

    Presynaptic kainate and N-methyl-d-aspartate receptors regulate excitatory amino acid release in the olfactory cortex

    Brain Res.

    (1983)
  • T.J. Crow

    Two syndromes in schizophrenia?

    Trends Neurosci.

    (1982)
  • T.J. Crow et al.

    Brain dopamine and behaviour: a critical analysis of the relationship between dopamine antagonism and therapeutic efficacy of neuroleptic drugs

    J. Psychiat. Res.

    (1974)
  • M.S. Desole et al.

    Neurochemical and behavioural changes induced by ascorbic acid and d-amphetamine in the rat

    Pharmac. Res. Commun.

    (1987)
  • M.S. Desole et al.

    Effects of cortical ablation on apomorphine-induced and scopolamine-induced changes in dopamine turnover and ascorbic acid catabolism in the rat striatum

    Eur. J. Pharmac.

    (1992)
  • M.S. Desole et al.

    The effects of cortical ablation on d- a phetamine-induced changes in striatal dopamine turnover and ascorbic acid catabolism in the rat

    Neurosci. Lett.

    (1992)
  • E.J. Diliberto et al.

    Mechanism of dopamine-β-hydroxylation

    J. biol. Chem.

    (1981)
  • R.L. Dorris et al.

    Potentiation of haloperidol-induced catalepsy by ascorbic acid in rats and nonhuman primates

    Pharmac. Biochem. Behav.

    (1986)
  • A. Dray

    The physiology and pharmacology of mammalian basal ganglia

    Prog. Neurobiol.

    (1980)
  • B. Drukarch et al.

    D-2 dopamine autoreceptor selective drugs: do they really exist?

    Life Sci.

    (1990)
  • A.G. Ewing et al.

    In vivo voltammetry with electrodes that discriminate between dopamine and ascorbate

    Brain Res.

    (1982)
  • A.G. Ewing et al.

    Simultaneous electrochemical and unit recording measurements: characterization of the effects of d-amphetamine and ascorbic acid on neostriatal neurons

    Brain Res.

    (1983)
  • B. Frei

    Ascorbic acid protects lipids in human plasma and low-density lipoprotein against oxidative damage

    Am. J. Clin. Nutr.

    (1991)
  • B.P.F. Adlard et al.

    The effect of age, growth retardation and asphyxia on ascorbic acid concentrations in developing brain

    J. Neurochem.

    (1973)
  • B.N. Ames et al.

    Oxidants, antioxidants, and the degenerative diseases of aging

  • A.C. Andorn et al.

    Guanyl nucleotide interactions with dopaminergic binding sites labeled by [3H]Spiroperidol in human caudate and putamen: guanyl nucleotides enhance ascorbate-induced lipid peroxidation and cause an apparent loss of high affinity binding sites

    Molec. Pharmac.

    (1988)
  • N.C. Andreasen et al.

    Schizophrenia—the characteristic symptoms

    Schiz. Bull.

    (1991)
  • E.B. Arushanian et al.

    The effect of amphetamine and caffeine on neuronal activity in the neocortex of the cat

    Neuropharmacology

    (1978)
  • P. Bach-y-Rita

    Neurotransmission in the brain by diffusion through the extracellular fluid

    Neuro Report

    (1993)
  • Cited by (320)

    View all citing articles on Scopus
    View full text